Accreditation

Target Audience

Advanced practitioners in the fields of urology, urogynecology, and genitourinary oncology.

Learning Objectives

Following the completion of this activity, participants should be able to:

• Discuss the current guidelines on risk stratification and management of both non-muscle invasive and muscle invasive Bladder Cancer.
• Determine optimal minimally invasive surgical therapy (MIST) of BPH options for the individual patient
• Describe various products and options for the management of stress urinary incontinence and overactive bladder.
• Examine the impact of translational research in Urologic conditions and current gaps in knowledge.
• Identify the treatment options available for SRM such as partial nephrectomy, ablative therapies, and active surveillance. Discuss the follow-up required for each treatment option.
• Describe the impact of various stone and patient factors on selection of surgical modality and treatment of patients with kidney stones.
• Identify various products and options for the management of stress urinary incontinence including artificial urinary sphincters, male urethral slings, and adjustable continence devices.
• Describe the capabilities for minimally invasive surgical platforms for the treatment of urethral and ureteral stricture disease, urinary fistulae, and other complex urinary abnormalities.

Requirements for Successful Completion

To receive CE credit, participants must sign-in, attend all or a portion of the activity (at least 80%), and complete and submit the activity evaluation provided in the syllabus materials. Partial credit may be awarded for the portion of the activity attended.

CineMed designates this live activity for 14 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other healthcare professionals participating in this activity will receive completion certificates verifying that the activity was designated for AMA PRA Category 1 Credit(s)™.